Company / Cash & Equivalents
ADMA Biologics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$87.6M
FY2025
5-year range
$51.1M / $103.1M
FY2021-FY2025
Trend
-15.0%
vs FY2024
Sector context
#151 of 207
Health Care
What the data says
At $88M, ADMA Biologics, Inc.'s cash & equivalents ranks #151 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $10M in FY2016 to $103M in FY2024.
Based on SEC 10-K filings.
$88M in FY2025 with a 5-year CAGR of +9.4%.
Improved from $51M to $88M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +0.4%
- 5-Year CAGR
- +9.4%
- 10-Year CAGR
- -
Sector benchmark
#151 of 207 in Health CareTop 73% of 207This company $87.6M Sector average $669.5M
▼
-86.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.4%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 15.0% year-over-year.
- Ranks #151 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $87.6M | -15.0% |
| FY2024 | $103.1M | +100.9% |
| FY2023 | $51.4M | -40.6% |
| FY2022 | $86.5M | +69.4% |
| FY2021 | $51.1M | -8.6% |
| FY2020 | $55.9M | +109.0% |
| FY2019 | $26.8M | -0.0% |
| FY2018 | $26.8M | -37.9% |
| FY2017 | $43.1M | +334.8% |
| FY2016 | $9.9M | -42.4% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026